Stock Events

Stock Events

Invion Limited 

$0.04
5
+$0.04+1,950% Monday 20:00

Statistics

Day High
0
Day Low
0
52W High
0.04
52W Low
0
Volume
2
Avg. Volume
0
Mkt Cap
3.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30AugExpected
Q2 2021
Q4 2021
Q2 2022
Q3 2022
Q2 2023
Q4 2023
Q2 2024
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-11.51MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IVIXF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a global healthcare company that develops medications and vaccines, including treatments in the oncology sector, directly competing with Invion's focus on cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is involved in biopharmaceuticals, particularly in cancer and immune system related therapies, overlapping with Invion's research and development in photodynamic therapies for cancer.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a large pharmaceutical company with a broad product line that includes oncology drugs, competing in the same market as Invion's cancer treatment technologies.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company focuses on pharmaceuticals including cancer treatments, which competes with Invion's therapeutic approaches in oncology.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong presence in the development of cancer treatments, particularly in areas that might overlap with Invion's therapeutic technologies.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is known for its extensive research and development in healthcare, including new cancer therapies that could compete with Invion's products.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. specializes in drugs for serious diseases including cancer, directly competing with Invion's focus areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotech firm focusing on human therapeutics, including cancer treatments that could rival Invion's product offerings.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a major player in diagnostics and pharmaceuticals, including cancer drugs, competing in the same space as Invion.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson engages in the development of pharmaceuticals, including oncology, which competes with Invion's cancer therapies.

About

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Show more...
CEO
Mr. Thian Chew
Country
AU
ISIN
AU000000IVX4

Listings

AU
AU
IVX.AU
F
DE
7C8.F
OTC Link
US
IVIXF

0 Comments

Share your thoughts

FAQ

What is Invion Limited stock price today?▼
The current price of IVIXF is $0.04 USD — it has increased by +1,950% in the past 24 hours. Watch Invion Limited stock price performance more closely on the chart.
What is Invion Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Invion Limited stocks are traded under the ticker IVIXF.
What is Invion Limited market cap?▼
Today Invion Limited has the market capitalization of 3.16M
What were Invion Limited earnings last quarter?▼
IVIXF earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Invion Limited revenue for the last year?▼
Invion Limited revenue for the last year amounts to 0 USD.
What is Invion Limited net income for the last year?▼
IVIXF net income for the last year is -11.51M USD.
In which sector is Invion Limited located?▼
Invion Limited operates in the Health Care sector.
When did Invion Limited complete a stock split?▼
The last stock split for Invion Limited was on November 20, 2024 with a ratio of 1:100.
Where is Invion Limited headquartered?▼
Invion Limited is headquartered in Melbourne, AU.